Clinical Trial Update: Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MRTX849 with cetuximab versus chemotherapy in advanced colorectal cancer with KRAS G12C mutation is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• MRTX849 (sotorasib)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING